Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 17, 2021

argenx reports positive data of efgartigimod in myasthenia gravis trial

The Phase III trial met the primary endpoint with efgartigimod showing improvement in the quality of life of patients.

argenx has reported positive results from the Phase III ADAPT clinical trial of efgartigimod in adults with generalised myasthenia gravis (gMG).

Efgartigimod is an investigational antibody fragment that can potentially lower disease-causing immunoglobulin G (IgG) antibodies and inhibit the IgG recycling process.

It attaches to the neonatal Fc receptor (FcRn), which is important for preventing the degradation of IgG antibodies. If approved, efgartigimod would be the first authorised FcRn antagonist.

The global, randomised, double-blind, placebo-controlled, multi-centre ADAPT trial assessed the safety and efficacy of the drug in 167 patients across North America, Europe and Japan.

Participants received efgartigimod or placebo over 26 weeks.

The primary endpoint was the number of acetylcholine receptor-antibody positive (AChR-Ab+) patients who experienced a response on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The MG-ADL response was determined as a minimum of a two-point improvement for at least four consecutive weeks.

The primary endpoint was met with significantly more AChR-Ab+ subjects responding on the MG-ADL score after treatment with efgartigimod versus placebo. Nearly 67% of patients treated with efgartigimod achieved a response compared to 29.7% on placebo.

Furthermore, 40% of participants in the efgartigimod arm showed minimal symptom expression determined as MG-ADL scores of zero (symptom free) or one, versus 11.1% in the placebo arm.

Among AChR-Ab+ responders, 84.1% had clinically meaningful improvement on the MG-ADL score in the initial two weeks of treatment.

The company added that the safety profile of efgartigimod was similar to that of placebo.

argenx chief medical officer Wim Parys said: “Efgartigimod is currently under review with the FDA for the treatment of gMG, and if approved, we look forward to bringing this therapy to MG patients who are in great need of new treatment options.”

After completing the ADAPT trial, 90% of subjects moved to an ongoing three-year open-label extension study, named ADAPT-plus, which is assessing the long-term safety and tolerability of the drug.

A total of at least 118 patients have received efgartigimod therapy for 12 months or more across the ADAPT and ADAPT-plus trials.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU